

Tzu-Fei Wang

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8333729/tzu-fei-wang-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93 papers	2,003 citations	20 h-index	44 g-index
106 ext. papers	2,721 ext. citations	5.6 avg, IF	4.8 L-index

#	Paper	IF	Citations
93	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018 , 378, 615-624	59.2	806
92	NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 1289-1303	7.3	105
91	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1439-1449	7	98
90	Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 88-93	7	98
89	Functional analysis of human hematopoietic stem cell gene expression using zebrafish. <i>PLoS Biology</i> , 2005 , 3, e254	9.7	86
88	Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1079-95	7.3	84
87	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1772-1778	15.4	62
86	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2019 , 94, 1176-1184	7.1	53
85	Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. <i>Thrombosis Research</i> , 2015 , 135, 616-20	8.2	49
84	Statins Are Associated With Reduced Mortality in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4008-4014	2.2	43
83	The role of thrombolytic therapy in pulmonary embolism. <i>Blood</i> , 2015 , 125, 2191-9	2.2	37
82	Risk factors for inpatient venous thromboembolism despite thromboprophylaxis. <i>Thrombosis Research</i> , 2014 , 133, 25-9	8.2	34
81	Aflibercept in the treatment of metastatic colorectal cancer. <i>Clinical Medicine Insights: Oncology</i> , 2012 , 6, 19-30	1.8	33
80	Managing thrombosis in cancer patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 429-438	5.1	29
79	Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. <i>Thrombosis Research</i> , 2020 , 185, 13-19	8.2	29
78	Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1247-1252	15.4	27
77	Anticoagulation Practice Patterns in COVID-19: A Global Survey. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 969	5.1	27

76	Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. <i>Thrombosis Research</i> , 2016 , 143, 86-90	8.2	25
75	Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1866-1874	15.4	23
74	A cross-sectional analysis of cardiovascular disease in the hemophilia population. <i>Blood Advances</i> , 2018 , 2, 1325-1333	7.8	22
73	What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 714-716	3.1	18
72	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	16
71	The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 278-284	15.4	13
70	The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. <i>Leukemia and Lymphoma</i> , 2014 , 55, 337-41	1.9	12
69	Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3174-3183	15.4	12
68	Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2377-2382	1.9	11
67	A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience. <i>Journal of Oncology Pharmacy Practice</i> , 2019 , 25, 793-800	1.7	11
66	How I treat obese patients with oral anticoagulants. <i>Blood</i> , 2020 , 135, 904-911	2.2	10
65	Predictive ability of the khorana score for venous thromboembolism (VTE) in multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18733-e18733	2.2	8
64	Presence and degree of residual venous obstruction on serial duplex imaging is associated with increased risk of recurrence and progression of infrainguinal lower extremity deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2018 , 6, 575-583.e1	3.2	8
63	Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. <i>Journal of Clinical Oncology</i> , 2012 , 30, e278-82	2.2	7
62	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. <i>British Journal of Haematology</i> , 2019 , 187, 399-402	4.5	6
61	A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1366-70	4.4	6
60	Thrombotic Complications Associated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021 , 13,	6.6	6
59	Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2468-2479	15.4	5

58	Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. <i>Cancer</i> , 2021 , 127, 938-945	6.4	5
57	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2068-2081	15.4	5
56	Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?. <i>Blood</i> , 2020 , 136, 669-673	6.3	4
55	Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multi-center cohort study. <i>Blood Advances</i> , 2021 ,	7.8	4
54	Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. <i>Blood Advances</i> , 2021 ,	7.8	4
53	Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers. <i>Cancer Management and Research</i> , 2020 , 12, 11743-11749	3.6	4
52	The Severity of Intracranial Hemorrhages Measured by Free Hemoglobin in the Brain Depends on the Anticoagulant Class: Experimental Data. <i>Stroke Research and Treatment</i> , 2017 , 2017, 6516401	1.7	3
51	Molecular structural analysis of a novel and de-novo mutation in the SERPINC1 gene associated with type 1 antithrombin deficiency. <i>British Journal of Haematology</i> , 2017 , 177, 654-656	4.5	3
50	Wide Variation in Duration of Anticoagulation after Catheter-Related Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. <i>Blood</i> , 2018 , 132, 1248-1248	2.2	3
49	A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. <i>Blood</i> , 2013 , 122, 5492-5492	2.2	3
48	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. <i>Blood</i> , 2014 , 124, 2836-2836	2.2	3
47	Comparison of Direct Oral Anticoagulants Versus Low-Molecular-Weight-Heparins for the Treatment of Cancer Associated Thrombosis. <i>Blood</i> , 2016 , 128, 5013-5013	2.2	3
46	Prediction of venous thromboembolism (VTE) in multiple myeloma (MM): Myeloma clot score (MCS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6585-6585	2.2	3
45	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	3
44	Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6, e12634	5.1	2
43	Optimal Timing for Removal of an Upper Extremity Central Catheter When Associated with a Deep Vein Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. <i>Blood</i> , 2019 , 134, 325-325	2.2	2
42	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. <i>Blood</i> , 2015 , 126, 761-761	2.2	2
41	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2021 , 208, 58-65	8.2	2

40	Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12517	5.1	2
39	Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps. <i>Oncologist</i> , 2021 , 26, e17-e23	5.7	2
38	Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 209S-216S	3.3	2
37	Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature. <i>Thrombosis Research</i> , 2021 , 204, 114-122	8.2	2
36	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 3008-3017	15.4	2
35	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial.. <i>Thrombosis Research</i> , 2022 , 211, 85-87	8.2	1
34	Incidence, characteristics, and risk factors of venous thromboembolism in adolescent and young adult acute lymphoblastic leukemia patients receiving peg-asparaginase.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18520-e18520	2.2	1
33	Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia. <i>International Journal of Hematologic Oncology</i> , 2020 , 9, IJH28	1	1
32	Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults.. <i>CJC Open</i> , 2022 , 4, 315-323	2	1
31	Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2021 , 1	3	1
30	North American Physician Practice Patterns in the Management of Anticoagulation in Pregnancy. <i>Journal of Women's Health</i> , 2021 , 30, 829-836	3	1
29	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021 , 202, 151-154	8.2	1
28	Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. <i>Thrombosis Research</i> , 2021 , 202, 155-161	8.2	1
27	Prevention and Treatment of Cancer-Associated Venous Thromboembolism: a Review. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019 , 21, 70	2.1	1
26	Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. <i>Blood Advances</i> , 2021 , 5, 2807-2812	7.8	1
25	Life dissatisfaction in Canadians aged 40 and above with cancer and mental health disorders: A cross-sectional study using the Canadian Community Health Survey. <i>Cancer Medicine</i> , 2021 , 10, 7601-7609	4.8	1
24	Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. <i>Thrombosis Research</i> , 2022 , 213, S66-S71	8.2	1
23	Safety and Efficacy of Apixaban Thromboprophylaxis in Ambulatory Cancer Patients By Renal Function: A Subgroup Analysis of the Avert Trial. <i>Blood</i> , 2021 , 138, 3229-3229	2.2	0

22	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021 , 208, 79-82	8.2	O
21	Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial. <i>Blood</i> , 2019 , 134, 1130-1130	2.2	O
20	A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 2021 , 32, 16-22	1	O
19	Thromboprophylaxis in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2020 , 190, 493-494	4.5	
18	Prospective Cohort of Catheter Related Thrombosis in Patients Treated with One Month of Anticoagulation after Catheter Removal. <i>Blood</i> , 2020 , 136, 36-37	2.2	
17	Maternal Outcomes in Women with Bleeding Disorders According to Mode of Delivery: A Single-Center Retrospective Cohort Study. <i>Blood</i> , 2021 , 138, 494-494	2.2	
16	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021 , 138, 2139-2139	2.2	
15	Rate of Clonal Hematopoiesis in Patients with Venous Thromboembolism. <i>Blood</i> , 2021 , 138, 4297-4297	2.2	
14	Bleeding Outcomes in Patients with Gastrointestinal Malignancies Treated with Distally Absorbed Versus Proximally Absorbed Direct Oral Anticoagulants. <i>Blood</i> , 2021 , 138, 3027-3027	2.2	
13	Survival in patients with cancer-associated thrombosis in relation to anticoagulants: Re-vitalization of warfarin?. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2677-2679	15.4	
12	Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score. <i>Blood</i> , 2018 , 132, 141-141	2.2	
11	A Retrospective Study of Clinical and Laboratory Characteristics in Patients Diagnosed with Platelet Storage Pool Deficiency. <i>Blood</i> , 2018 , 132, 1148-1148	2.2	
10	Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study. <i>Blood</i> , 2018 , 132, 2479-2479	2.2	
9	Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment. <i>Blood</i> , 2018 , 132, 3148-3148	2.2	
8	Recurrent and de-novo autoimmune hemolytic anemia in patients treated with immunotherapy for advanced cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14170-e14170	2.2	
7	Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks. <i>Blood</i> , 2019 , 134, 3681-3681	2.2	
6	Analysis of bleeding risk with concurrent treatment of VEGFR tyrosine kinase inhibitors (TKIs) and factor Xa inhibitors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19305-e19305	2.2	
5	Von Willebrand Factor for Menorrhagia: A Survey and Literature Review. <i>Blood</i> , 2015 , 126, 4694-4694	2.2	

4	Risk Factors for Inpatient Acute Venous Thromboembolism (VTE) Despite Thromboprophylaxis.. <i>Blood</i> , 2012 , 120, 2248-2248	2.2
3	Higher Doses of Prophylactic Anticoagulation Is More Effective in Preventing Venous Thromboembolism in Morbidly Obese Inpatients.. <i>Blood</i> , 2012 , 120, 2268-2268	2.2
2	The Incidence, Characteristics, and Outcomes of Venous Thromboembolism in Patients with Follicular Lymphoma Compared to Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012 , 120, 5090-5090	2.2
1	New onset of acute heavy menstrual bleeding in a 34-year-old woman. <i>Cmaj</i> , 2021 , 193, E1173-E1176	3.5